Ticker Details
AnaptysBio, Inc. AnaptysBio Inc is a biotechnology company. The company is engaged in developing first-in-class antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. Its product include ANB020 and ANB019.
IPO Date:	January 26, 2017
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.97B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.97 | 2.66%
Avg Daily Range (30 D):	$1.89 | 3.13%
Avg Daily Range (90 D):	$1.36 | 2.58%

Institutional Daily Volume
Avg Daily Volume:	.31M
Avg Daily Volume (30 D):	.49M
Avg Daily Volume (90 D):	.41M

Trade Size
Avg Trade Size (Sh.):	72
Avg Trade Size (Sh.) (30 D):	52
Avg Trade Size (Sh.) (90 D):	53

Institutional Trades
Total Institutional Trades:	3,285
Avg Institutional Trade:	$1.75M
Avg Institutional Trade (30 D):	$2.25M
Avg Institutional Trade (90 D):	$2.43M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.79M
Avg Closing Trade (30 D):	$4.46M
Avg Closing Trade (90 D):	$3.43M
Avg Closing Volume:	53.71K

News

Jan 8, 2026 @ 11:00 PM Anaptys Files Motion to Dismiss Tesaro’s Cl... Source: Na

Nov 21, 2025 @ 1:48 PM GSK Unit Tesaro Sues AnaptysBio, Threatening Key C... Source: Vandana Singh

Nov 21, 2025 @ 8:50 AM Anaptys Initiates Litigation Against Tesaro, a GSK... Source: Anaptysbio

Sep 29, 2025 @ 9:06 PM 12 Health Care Stocks Moving In Monday's After-Mar... Source: Benzinga Staff Writer

Apr 14, 2025 @ 5:00 PM Psoriasis Market Outlook in the 7MM Through 2034: ... Source: Delveinsight

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-.46	$1.7	$-.46
Diluted EPS	$-.46	$1.7	$-.46
Revenue	$234.6M	$108.25M	$234.6M
Gross Profit
Net Income / Loss	$-13.23M	$49.61M	$-13.23M
Operating Income / Loss	$47.9M	$66.9M	$47.9M
Cost of Revenue
Net Cash Flow	$115.12M	$128.36M	$115.12M
PE Ratio